Puma Biotechnology Investor Presentation — March 2021

Document content

Barclays Global Healthcare Conference

This presentation contains forward -looking statements, including statements regarding commercialization ofNERLYNX® andthepotential indications

and development ofourdrug candidates .Allforward -looking statements involve risks anduncertainties thatcould cause ouractual results todiffer

materially from theanticipated results andexpectations expressed inthese forward -looking statements .These statements arebased onourcurrent

expectations, forecasts andassumptions, andactual outcomes andresults could differ materially from these statements duetoanumber offactors,

which include, butarenotlimited to,anyadverse impact onourbusiness ortheglobal economy andfinancial markets, generally, from theglobal

COVID -19pandemic, andtheriskfactors disclosed inourperiodic andcurrent reports filed with theSecurities andExchange Commission from time to

time, including ourAnnual Report onForm 10-Kfortheyear ended December 31,2020 .Readers arecautioned nottoplace undue reliance onthese

forward -looking statements, which speak only asofthedate hereof .Weassume noobligation toupdate these forward -looking statements except as

required bylaw.Forward -Looking Safe -Harbor Statement3

Copyright 2021 Puma BiotechnologyProduct Pipeline

Neratinib across the breast cancer therapy spectrum

Phase I Phase II Phase III Registration Approval

Neratinib monotherapy

Monotherapy or combo therapy

Metastatic w/ brain mets

Monotherapy or combo therapy

Neratinib ( ±fulvestrant in MBC)NSABP FB -7

NALA (Phase III 3rdLine HER2+ MBC**)

FB-10: T -DM1 + neratinib

ExteNET (Phase III HER2+ EBC*)